Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sage Therapeutics, Inc. - Common Stock (NQ: SAGE )

7.500 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Sage Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Artificial Intelligence Could Be About To Replace Your Doctor
FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – November 2, 2021 – The US health and medical insurance industry is a $1.1-trillion maze that is impossible to navigate. And... 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Sage Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Ketamine’s Potential As A Treatment For Depression Has Drawn Major Industry Attention
Palm Beach, FL –October 27, 2021 – FinancialNewsMedia.com News Commentary – Among the race to see what psychedelic drugs can do, ketamine is a step ahead of all other drugs, because it has already been... 
Via FinancialNewsMedia
Exposures Product Safety
Sage Therapeutics to Report Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022
From Sage Therapeutics, Inc.
Via Business Wire
A.I. Breakthrough Could Disrupt the $11 Trillion Medical Sector
FN Media Group Presents Oilprice.com Market Commentary London – October 18, 2021 – A massive disruption now appears imminent in one of the world’s largest – and most important – industries. In much the... 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Sage Therapeutics and Biogen Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and NEST Clinical Development Programs Presented at the European College of Neuropsychopharmacology (ECNP) Congress
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Launches SageCitizen Social Impact Initiative
From Sage Therapeutics
Via Business Wire
Sage Therapeutics Appoints Chris Benecchi as Chief Commercial Officer
From Sage Therapeutics
Via Business Wire
Sage Therapeutics Receives Fast Track Designation for SAGE-718 for the Treatment of Huntington’s Disease
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Present at the Morgan Stanley Global Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Present at Upcoming August Investor Conferences
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Participate in Cowen’s Psychedelics & Novel Mechanisms in Neuropsychiatry Summit
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Participate in SVB Leerink’s 3rd Annual CNS Forum
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Host Conference Call
From Sage Therapeutics
Via Business Wire
Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Joins MTV Entertainment Group and More Than 1,300 Leading Organizations to Participate in Inaugural Mental Health Action Day
From Sage Therapeutics
Via Business Wire
Betting Big On What Could Be The Next Great Biotech Boom
Via FinancialNewsMedia
Sage Therapeutics to Host Sage Science Spotlight: SAGE-718 In Depth
From Sage Therapeutics
Via Business Wire
Sage Therapeutics Announces First Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Present at Upcoming May Investor Conferences
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Report First Quarter 2021 Financial Results on Tuesday, May 4, 2021
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint
From Sage Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.